Status:
UNKNOWN
Role of Urinary Claudin-2, Caveolin-1, and EGF as Diagnostic Biomarkers of Necrotizing Enterocolitis in Preterm Neonates
Lead Sponsor:
University of Brawijaya
Conditions:
Enterocolitis, Necrotizing
Infant, Premature
Eligibility:
All Genders
1-28 years
Brief Summary
Our study aims to determine the differences in the concentration of urinary claudin-2, caveolin-1, and epidermal growth factor (EGF) as non-invasive biomarkers in the diagnosis of Necrotizing Enteroco...
Detailed Description
Necrotizing enterocolitis (NEC) is a multifactorial syndrome of acute intestinal ischemic necrosis which is one of the acute intestinal emergencies in neonates with high morbidity and mortality rates ...
Eligibility Criteria
Inclusion
- Inclusion Criteria of Subjects:
- Premature neonates with 28-34 weeks' gestational age
- Admitted in Perinatology Unit, Saiful Anwar General Hospital, Malang
- Parents/guardians have agreed and signed the informed consent of the study
- Neonates receive nutrition from breast milk or breast milk predominance
- NEC was diagnosed using Bell's modification criteria.
- Inclusion Criteria of Control:
- Premature neonates with 28-34 weeks' gestational age, admitted in Perinatology Unit, Saiful Anwar General Hospital, Malang. Parents/guardians have agreed and signed the informed consent of the study. Neonates receive nutrition from breast milk or breast milk predominance.
- Term neonates with 37-42 weeks' gestational age, admitted in Perinatology Unit, Saiful Anwar General Hospital, Malang. Parents/guardians have agreed and signed the informed consent of the study. Neonates receive nutrition from breast milk or breast milk predominance.
- Exclusion Criteria:
- Treated neonates who died during the study before the diagnosis of NEC was established
- Neonates whom require surgery during the study
- Parents/guardians stated that they were not willing to participate in the study.
Exclusion
Key Trial Info
Start Date :
March 17 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05335577
Start Date
March 17 2022
End Date
July 1 2022
Last Update
April 19 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Saiful Anwar General Hospital
Malang, East Java, Indonesia, 65111